AZ and Novartis veteran Tommasi to lead R&D at Dunad
Plus new CSOs at Atomwise and Sotio, and updates from Nine Square, Fabric and Biolojic Design
Protein degradation company Dunad Therapeutics Ltd. hired Ruben Tommasi as chief R&D officer. Tommasi joins Dunad from Entasis Therapeutics Inc., a spin out of AstraZeneca plc (LSE:AZN; NASDAQ:AZN) where he served as head of infectious disease chemistry. Prior to AstraZeneca, he spent nearly 17 years at Novartis AG (SIX:NOVN; NYSE:NVS). Dunad recruited a new CEO in June and partnered its non-E3 protein degrader platform with Novartis last year.
Gavin Hirst became CSO at Atomwise Inc., which is discovering small molecules using AI. Hirst was interim CSO and SVP of chemistry at Turning Point Therapeutics Inc. before that company’s acquisition by Bristol Myers Squibb Co. (NYSE:BMY) in August. Hirst also worked at Janssen Pharmaceuticals. ...